NCT04479163View on ClinicalTrials.gov

Prevention of Severe Covid-19 in Infected Elderly by Early Administration of Convalescent Plasma With High-titers of Antibody Against SARS-CoV2

NACompletedINTERVENTIONAL

Enrollment

165

Participants

Timeline

Start Date

June 4, 2020

Primary Completion Date

October 25, 2020

Study Completion Date

October 25, 2020

Conditions

COVID

Interventions

BIOLOGICAL

Convalescent Plasma

250 ml Convalescent plasma with an IgG titer against SARS CoV2

OTHER

Placebo

Normal Saline 0.9%

Trial Locations (11)

1426

Hospital Militar Central, CABA

Unknown

CEMIC, CABA

Centro de Investigacion Clinica OSECAC, CABA

Centro Gallego de Buenos Aires, CABA

Sanatorio Anchorena, CABA

Sanatorio de Los Arcos, CABA

"Hospital Simplemente Evita", González Catán

"Hospital Especializado de Agudos y Crónicos San Juan de Dios", La Plata

Clinica Olivos, Buenos Aires

Hospital Central de San Isidro, Buenos Aires

"Hospital General de Agudos Dr. Carlos Bocalandro", Buenos Aires

All Listed Sponsors

lead

Fundacion Infant

OTHER

NCT04479163 - Prevention of Severe Covid-19 in Infected Elderly by Early Administration of Convalescent Plasma With High-titers of Antibody Against SARS-CoV2 | Biotech Hunter | Biotech Hunter